


# Prostate cancer treatment can wait for most men, study finds

March 12 2023, by Carla K. Johnson

---



This 1974 microscope image made available by the Centers for Disease Control and Prevention shows changes in cells indicative of adenocarcinoma of the prostate. A study published by the New England Journal of Medicine on Saturday, March 11, 2023, finds long-term evidence that actively monitoring prostate cancer can be a safe alternative to immediate surgery or radiation. Credit: Dr. Edwin P. Ewing, Jr./CDC via AP

Researchers have found long-term evidence that actively monitoring localized prostate cancer is a safe alternative to immediate surgery or radiation.

The results, released Saturday, are encouraging for men who want to avoid treatment-related sexual and incontinence problems, said Dr. Stacy Loeb, a [prostate cancer](#) specialist at NYU Langone Health who was not involved in the research.

The study directly compared the three approaches—[surgery](#) to remove tumors, [radiation treatment](#) and [monitoring](#). Most prostate cancer grows slowly, so it takes many years to look at the disease's outcomes.

"There was no difference in [prostate cancer mortality](#) at 15 years between the groups," Loeb said. And prostate cancer survival for all three groups was high—97% regardless of treatment approach. "That's also very good news."

The results were published Saturday in the *New England Journal of Medicine* and presented at a European Association of Urology conference in Milan, Italy. Britain's National Institute for Health and Care Research paid for the research.

Men diagnosed with localized prostate cancer shouldn't panic or rush treatment decisions, said lead author Dr. Freddie Hamdy of the University of Oxford. Instead, they should "consider carefully the possible benefits and harms caused by the [treatment options](#)."

A small number of men with high-risk or more advanced disease do need urgent treatments, he added.

Researchers followed more than 1,600 U.K. men who agreed to be randomly assigned to get surgery, radiation or active monitoring. The

patients' cancer was confined to the prostate, a walnut-sized gland that's part of the reproductive system. Men in the monitoring group had regular blood tests and some went on to have surgery or radiation.

Death from prostate cancer occurred in 3.1% of the active-monitoring group, 2.2% in the surgery group, and 2.9% in the radiation group, differences considered statistically insignificant.

At 15 years, cancer had spread in 9.4% of the active-monitoring group, 4.7% of the surgery group and 5% of the radiation group. The study was started in 1999, and experts said today's monitoring practices are better, with MRI imaging and gene tests guiding decisions.

"We have more ways now to help catch that the disease is progressing before it spreads," Loeb said. In the U.S., about 60% of low-risk patients choose monitoring, now called active surveillance.

Hamdy said the researchers had seen the difference in cancer spread at 10 years and expected it to make a difference in survival at 15 years, "but it did not." He said spread alone doesn't predict [prostate cancer](#) death.

"This is a new and interesting finding, useful for men when they make decisions about treatments," he said.

**More information:** Freddie C. Hamdy et al, Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer, *New England Journal of Medicine* (2023). DOI: 10.1056/NEJMoa2214122 , [www.nejm.org/doi/10.1056/NEJMoa2214122](http://www.nejm.org/doi/10.1056/NEJMoa2214122)

Oliver Sartor, Localized Prostate Cancer—Then and Now, *New England Journal of Medicine* (2023). DOI: 10.1056/NEJMe2300807 , [www.nejm.org/doi/full/10.1056/NEJMe2300807](http://www.nejm.org/doi/full/10.1056/NEJMe2300807)

© 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: Prostate cancer treatment can wait for most men, study finds (2023, March 12)  
retrieved 19 April 2024 from  
<https://medicalxpress.com/news/2023-03-prostate-cancer-treatment-men.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.